Craft

Advanced
  • Home
  •  / Homology Medicines
Homology Medicines

Homology Medicines

Revenue

$53.7 M

FY, 2025

Homology Medicines Summary

Company Summary

Overview
Homology Medicines is a healthcare company specializing in genetics. It offers gene editing and gene therapy clinical-stage programs in PKU and Hunter syndrome. The company was merged with Q32 Bio.
Type
Subsidiary
Status
Closed
Founded
2015
HQ
Bedford, MA, US | view all locations
Website
http://www.homologymedicines.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Kush M. Parmar, Director

    • Brad Smith

    • Steven Gillis, Director

      • Richard Gregory, Director

        LocationsView all

        1 location detected

        • Bedford, MA HQ

          United States

          1 Patriots Park

        Homology Medicines Financials

        Summary Financials

        Net income (Q1, 2026)
        ($7.6M)
        Cash (Q1, 2026)
        $50.8M
        EBIT (Q1, 2026)
        ($7.7M)

        Competitors and Similar Companies

        Compare competitors

        Footer menu

        Product

        Solutions

        Resources

        Company

        © Craft.co 2026
        Share price data provided by IEX